On Friday, Siliconware Precision Industries (ADR) (NASDAQ:SPIL)’s shares inclined 24.13% to $6.43.
Siliconware Precision Industries Co., Ltd. (SPIL) (Taiwan Stock Exchange: 2325.TT, NASDAQ: SPIL) declared that regarding the declarement of Advanced Semiconductor Engineering, Inc. (“ASE”) to propose a tender offer for SPIL’s common shares and/or ADSs, the Company was not aware of such matter in advance.
The Company will take all actions in accordance with the applicable laws upon receipt of the public tender offer prospectus, and will provide a formal response, together with recommendation and explanations, to the Company’s shareholders within seven (7) days.
Siliconware Precision Industries Co., Ltd. provides semiconductor packaging and testing services to semiconductor suppliers worldwide. Its packaging and testing solutions comprise advanced packages, substrate packages, and lead-frame packages, in addition to testing for logic and mixed signal devices to measure and ensure the performance, functionality, and reliability of packaged semiconductor devices.
Hecla Mining Company (NYSE:HL)’s shares dropped -5.29% to $2.15.
Hecla Mining Company (NYSE:HL) declared its Board of Directors has elected to declare the regular quarterly dividend of $0.875 per share on the outstanding Series B Cumulative Convertible Preferred Stock, on a total of 157,816 shares outstanding. This represents a total amount to be paid of about $138,000. The cash dividend is payable October 1, 2015, to shareholders of record on September 15, 2015.
Hecla Mining Company, together with its auxiliaries, discovers, acquires, develops, produces, and markets precious and base metal deposits worldwide. The company offers unrefined gold and silver bullion bars to precious metals traders; and lead, zinc, and bulk concentrates to custom smelters and brokers. It owns 100% interests in the Greens Creek mine located on Admiralty Island in Southeast Alaska; the Lucky Friday unit located in the Coeur dAlene mining district in northern Idaho; and the Casa Berardi mine located in the Abitibi region of north-western Quebec, Canada.
At the end of Friday’s trade, Discovery Communications Inc. (NASDAQ:DISCA)‘s shares dipped -0.81% to $27.10.
Discovery Communications, Inc. (DISCA) stated financial results for the second quarter ended June 30, 2015.
Second Quarter Results
Second quarter revenues of $1,654 million raised $44 million, or 3%, over the second quarter a year ago, led by 5% growth at U.S. Netoperates and 1% growth at International Netoperates. Adjusted Operating Income Before Depreciation and Amortization(1) (“OIBDA”) reduced 2% to $680 million, as 7% growth at U.S. Netoperates was more than offset by an 11% decline at International Netoperates and a small operating loss at Education and Other. Total Company revenues grew 11% and Adjusted OIBDA grew 6% not taking into account currency effects, as changes in foreign currency exchange rates reduced both second quarter revenue and Adjusted OIBDA growth by 8%. Not taking into account currency effects, the impact of Eurosport(2) and the consolidation of Discovery Family, total Company revenues raised 4% and Adjusted OIBDA raised 3%.
Discovery Communications, Inc. operates as a media company. The company operates through U.S. Netoperates; International Netoperates; and Education and Other segments. The company owns and operates television netoperates under the brands, such as Discovery, TLC, Animal Planet, Investigation Discovery, Science, Velocity, Discovery Family, American Heroes, Destination America, Discovery Life, Oprah Winfrey network, Eurosport, DMAX, and Discovery Kids. Its content spans genres, counting survival, exploration, sports, lifestyle, general entertainment, heroes, adventure, crime and investigation, health, and kids.
Celsus Therapeutics PLC (ADR) (NASDAQ:CLTX), ended its Friday’s trading session with -6.75% loss, and closed at $2.90.
Celsus Therapeutics Plc (CLTX) and Volution Immuno Pharmaceuticals SA declared that Celsus has reached a securities purchase agreement for a private placement with a select group of investors, led by Deerfield, and counting Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Administration and certain other institutional investors.
The closing of the private placement is subject to Celsus obtaining shareholder approval of the financing transaction and the formerly declared acquisition by Celsus of Volution Immuno Pharmaceuticals at Celsus’ General Shareholder Meeting on September 16, 2015, the closing of the acquisition and satisfaction of customary closing conditions. Following the closing of the acquisition, the combined company will be renamed Akari Therapeutics Plc, and the company anticipates to trade on the NASDAQ Capital Market under the ticker symbol ‘AKTX’.
Celsus Therapeutics Plc, a development stage biopharmaceutical company, engages in the discovery and development of non-steroidal, synthetic anti-inflammatory drugs. The company’s principal product candidate is MRX-6, a topical cream that is in Phase 2 clinical trial for the treatment of atopic dermatitis. Its product candidates in pre-clinical studies comprise OPT-1 for the treatment of conjunctivitis, post-operative inflammation, and/or dry eye; CFX-1 to treat cystic fibrosis; and OAX-1 for the treatment of osteoarthritis and other inflammatory diseases.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
